Latest Videos |view all videos
Population Screening for Barrett's Esophagus
Dr. Ganapathy A. Prasad, Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester, MN, discusses his article appearing in the December 2011 issue of Mayo Clinic Proceedings.
Nonclonal serum immunoglobulin free light chains to predict overall survival
S. Vincent Rajkumar, M.D., reviews his Olmsted County population-based study investigating the detection of high polyclonal free light chain levels as a predictor of mortality outcomes across multiple conditions.
New developments in the medical management of prostate cancer
Manish Kohli, M.D., of Mayo Clinic, discusses his January 2010 Mayo Clinic Proceedings article on new developments in the medical management of prostate cancer.
Monoclonal gammopathy-associated proliferative glomerulonephritis — S. Vincent Rajkumar, M.D.
S. Vincent Rajkumar, M.D., in the Department of Hematology at Mayo Clinic, introduces and explains the importance of recognizing monoclonal gammopathies as a major cause of proliferative glomerulonephritis.
Monoclonal gammopathy-associated proliferative glomerulonephritis — Sanjeev Sethi, M.D., Ph.D.
Sanjeev Sethi, M.D., Ph.D., a professor of laboratory medicine and pathology at Mayo Clinic, presents findings that define the role of monoclonal proteins in proliferative glomerulonephritis and propose evaluation and new treatment algorithms ...
Metabolic Syndrome as a Risk Factor for Barrett's Esophagus
Noting a 2-fold increase in risk of Barrett's Esophagus, Dr. Cadman Leggett, a fellow in gastroenterology at Mayo Clinic in Rochester, MN, discusses his article appearing in the February 2013 issue of Mayo Clinic Proceedings.
Melanoma in immunosuppressed patients
Jerry D. Brewer, M.D., M.S., a dermatologic surgeon from the Department of Dermatology at Mayo Clinic in Rochester, Minnesota, unmasks a previously unknown higher risk of melanoma in immunosuppressed and transplant patients.
Mayo oral cancer study shows full tumor genome
Mayo Clinic researchers along with collaborators from Life Technologies are reporting on the application of a new approach for sequencing RNA to study cancer tumors.
Mayo Clinic study suggests routine prostate size evaluation not as effective in cancer screening
If a man's PSA is quickly rising, he likely deserves a prostate biopsy to determine if he has prostate cancer. Assessment of change in prostate size should not influence the decision to biopsy. Dr. Rodney Breau discusses the study and ...
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of people with metastatic colorectal cancer, an international phase III clinical trial found.
Biopsy-based predictors of prostate cancer mortality: The Mayo Model
Matthew K. Tollefson, M.D., provides patients and clinicians with a novel way to predict which cases of prostate cancer, the most commonly diagnosed malignancy in American men, will be aggressive and which ones can be safely monitored with watchful waiting.
Grand Rounds en Español: Desarrollos Recientes en Medicina de Cáncer
Gerardo Colon-Otero, M.D., Desarrollos Recientes en Medicina de Cáncer Presentado el 25 de Septiembre, 2013 en la Clínica Mayo.